Orum Therapeutics, Inc. (KOSDAQ:475830)

South Korea flag South Korea · Delayed Price · Currency is KRW
91,500
+3,200 (3.62%)
Apr 28, 2026, 3:30 PM KST
258.82%
Market Cap 1.94T
Revenue (ttm) 23.56M
Net Income (ttm) -41.97B
Shares Out 21.23M
EPS (ttm) -2,017.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 220,255
Average Volume 215,458
Open 87,500
Previous Close 88,300
Day's Range 85,400 - 91,500
52-Week Range 15,950 - 146,600
Beta n/a
RSI 50.01
Earnings Date Apr 3, 2026

About Orum Therapeutics

Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases. The company develops BMS-986497 (ORM-6151), which is in phase 1 clinical trial to treat acuta myeloid leukemia and high-risk myelodysplastic syndromes; ORM-1153, which is in preclinical trial to treat acuta myeloid leukemia and heme-onc; and ORM-1023, which is in preclinical trial for the treatment of small cell lung cancer and neuroendocrine tumor. It also develops multiple programs; and E3 Ligase-DAC... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 475830
Full Company Profile

Financial Performance

In 2025, Orum Therapeutics's revenue was 23.56 million, a decrease of -99.89% compared to the previous year's 20.91 billion. Losses were -41.97 billion, 631.2% more than in 2024.

Financial Statements

News

There is no news available yet.